- Dosing is underway in a Phase 1 study evaluating the safety and pharmacokinetics of Cara Therapeutics' (NASDAQ:CARA +2.3%) Oral KORSUVA (difelikefalin) in patients with chronic liver disease (CLD). The open-label trial will enroll up to 60 subjects with CLD and up to 12 healthy patients for control.
- Results will inform the design of a Phase 2 clinical trial in patients with moderate-to-severe CLD-associated pruritis.
- KORSUVA is a peripherally acting kappa opioid receptor agonist that is also being developed for the treatment of acute and chronic pain. Its value proposition is opioid-like analgesia without the respiratory depression or intestinal tract inhibition (constipation).
- Previously: Cara Therapeutics launches late-stage study of CR845 in CKD-aP (Jan. 31)